# BMPR1A

Source: https://onco.cc/targets/bmpr1a/  
OnCo record `bmpr1a` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BMPR1A (Bone morphogenetic protein receptor type-1A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Breast cancer and 1 more.

## Summary

On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6.

Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.90, genetic association 0.69, somatic mutation 0.83, genetic literature 0.61). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Stomach Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: bone morphogenetic protein receptor type 1A; Bone morphogenetic protein receptor type-1A; ALK3; CD292; ACVRLK3
- Tags: cancer-genes-wave
- Symbol: BMPR1A
- Class: kinase
- Biology: On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6. May promote the expression of HAMP, potentially via its interaction with BMP2. Location: Cell membrane; Cell surface (UniProt). Locus 10q23.2 (HGNC).
- Where found: Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD); Colorectal cancer: Open Targets association 0.56 with colorectal cancer (MONDO_0005575); Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254); Ovarian cancer: Open Targets association 0.54 with ovarian cancer (MONDO_0008170)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1076: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1076
- UniProt P36894: https://www.uniprot.org/uniprotkb/P36894/entry
- NCBI Gene 657: https://www.ncbi.nlm.nih.gov/gene/657
- Ensembl ENSG00000107779: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107779

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/bmpr1a.json